Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAvalon Flow Cytometry Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentAvalon Healthcare SolutionsPolicy AHS-F2019

    Flow Cytometry

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS-F2019 alerts

    Get alerted when Policy AHS-F2019 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and reimbursement of flow cytometry, including immunophenotyping, cell enumeration, specimen and marker limits, and DNA content or S-phase testing. It applies to members whose benefits are subject to Avalon Healthcare Solutions policy and to applicable Medicare or Medicaid government coverage requirements.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyFlow Cytometry
    Policy CodePolicy N/A
    Change TypeRevision
    Effective DateFeb 1, 2026
    Last ReviewOct 31, 2025
    Next Review DateN/A
    Key ActionSelect the initial flow cytometry reagent panel based on specimen type, clinical information, and cell morphology studies.
    SourceLink
    POLICY UPDATE CHANGES

    The policy expanded the covered indication for cytopenias, lymphomas, leukemia, myeloproliferative and lymphoproliferative disorders, or myelodysplastic syndrome and removed repetitive chronic lymphocytic leukemia and chronic myeloproliferative disorder criteria.

    CPT code 88199 was removed from the policy.

    The policy added a noncoverage statement for flow cytometry-derived DNA content, DNA index, S-phase fraction, or percentage S-phase used for prognostic or therapeutic purposes in routine cancer management.

    Flow cytometry for minimal residual disease is covered in accordance with Avalon Policy AHS M2175-Minimal Residual Disease (MRD).

    The policy removed molar pregnancy as a flow cytometry indication because molar pregnancy screening is no longer performed by flow cytometry.

    The organ transplantation indication was revised to include both preoperative and postoperative monitoring.

    The policy clarified that codes 88187, 88188, and 88189 must not be used together for a single specimen.

    The policy added that codes 88187, 88188, and 88189 are reimbursed at one unit per specimen for up to two specimens per date of service.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10Covered clinical indications
    88184–88189Immunophenotyping code range
    35Maximum additional-marker units per day
    2Maximum first-marker units per day
    Not coveredRoutine cancer DNA/S-phase testing
    1MRD cross-policy requirement

    Coverage Criteria

    Covered flow cytometry immunophenotyping indications

    Flow cytometry immunophenotyping of cell surface markers meets coverage criteria when any of the following indications applies.

    Covered indications

    • Cytopenias or hematologic disorders: The individual has cytopenias, lymphomas, leukemia, myeloproliferative disorders, lymphoproliferative disorders, or myelodysplastic syndrome.
    • B-cell monitoring is performed for an immunosuppressive disorder.
    • T-cell monitoring is performed for HIV infection or AIDS.
    • Mast cell neoplasms: The individual has a mast cell neoplasm.
    • Paroxysmal nocturnal hemoglobinuria: The individual has paroxysmal nocturnal hemoglobinuria.
    • Organ transplantation monitoring: The test is used for preoperative or postoperative monitoring of an individual who will undergo or has undergone organ transplantation.
    • Plasma cell disorders: The individual has a plasma cell disorder.
    • Primary immunodeficiencies: The individual has a primary immunodeficiency.
    • Primary platelet disorders: The individual has a non-neoplastic primary platelet disorder.
    • Red-cell or white-cell disorders: The individual has a non-neoplastic red-cell or white-cell disorder.

    Reimbursement limitations for immunophenotyping

    Reimbursement for covered flow cytometry services is subject to the following coding and medical-necessity limitations.

    Immunophenotyping reimbursement requirements: For assessment of potential hematolymphoid neoplasia, use codes 88184–88189. Use code 88184 for the first marker per specimen and code 88185 for each additional marker. When a neoplasm has an established immunophenotype, subsequent testing must be limited to diagnostically relevant markers. Codes 88187, 88188, and 88189 must not be used together for a single specimen or with codes 86355, 86356, 86357, 86359, 86360, 86361, or 86367. Cell-enumeration codes 86355, 86357, 86359, 86360, 86361, and 86367 are reimbursable as single units only.

    Code 88184 is limited to 2 units per date of service; code 88185 is limited to 35 units per date of service; codes 88187–88189 are limited to 1 unit per specimen for up to 2 specimens per date of service.

    Not covered routine DNA content or S-phase testing

    The following service does not meet coverage criteria.

    Routine cancer DNA or proliferation testing: Measurement of flow cytometry-derived DNA content (DNA Index) or cell proliferative activity (S-phase fraction or percentage S-phase) is performed for prognostic or therapeutic purposes in the routine clinical management of cancer.

    The policy attributes noncoverage to insufficient published scientific literature confirming that the testing is required and beneficial for diagnosis and treatment.

    Hematolymphoid evaluation

    Flow cytometry is useful when clinically indicated for evaluation of hematolymphoid disease or selected monitoring purposes.

    • The individual has cytopenias.
    • The individual has an elevated leukocyte count.
    • Atypical cells or blasts are observed.
    • Evaluation of a body fluid is clinically indicated.
    • The individual has plasmacytosis or monoclonal gammopathy.
    • The individual has organomegaly or a tissue mass.

    Acute leukemia diagnosis and monitoring

    For suspected or confirmed acute leukemia, flow cytometric immunophenotyping should be performed with other diagnostic studies.

    Acute leukemia workup: For suspected or confirmed acute leukemia, obtain sufficient samples and perform morphologic assessment, conventional cytogenetic analysis, appropriate molecular genetic and/or FISH testing, and flow cytometric immunophenotyping. The flow cytometry panel must distinguish acute myeloid leukemia, T-cell acute lymphoblastic leukemia, B-cell precursor acute lymphoblastic leukemia, and acute leukemia of ambiguous lineage.

    If sufficient bone marrow aspirate or peripheral blood is unavailable, limited immunophenotyping by immunohistochemistry may be used as an alternative.

    Minimal residual disease capability: For suspected or confirmed acute leukemia, flow cytometry analysis or molecular characterization must be comprehensive enough to permit subsequent detection of minimal residual disease.

    Platelet disorder testing

    Flow cytometric analysis may be useful in selected inherited and acquired platelet disorders.

    Platelet disorder applications

    • Diagnosis of inherited or acquired platelet surface glycoprotein deficiencies.
    • Diagnosis of platelet alpha-granule secretion defects.
    • Diagnosis of defects in platelet activation or signaling pathways.
    • Diagnosis of GFI1B macrothrombocytopenia associated with platelet CD34 expression.
    • Diagnosis of platelet procoagulant activity disorders.

    Clinical indications

    Coverage includes the following clinical indications.

    Covered clinical indications

    • The individual has cytopenias, lymphomas, leukemia, myeloproliferative or lymphoproliferative disorders, or myelodysplastic syndrome.
    • The test is used for preoperative or postoperative monitoring of an individual who will undergo or has undergone organ transplantation.
    • The individual has a primary immunodeficiency.

    Minimal residual disease

    Covered subject to the separate Avalon policy.

    Minimal residual disease: Flow cytometry for minimal residual disease is covered in accordance with Avalon Policy AHS M2175-Minimal Residual Disease (MRD).

    Apply the separate MRD policy for the coverage determination.

    DNA content and cell proliferative activity

    The following does not meet coverage criteria.

    Routine cancer prognostic or therapeutic testing: Measurement of flow cytometry-derived DNA content, DNA Index, S-phase fraction, or percentage S-phase is used for prognostic or therapeutic purposes in the routine clinical management of cancers.

    Noncoverage is based on insufficient published scientific literature confirming that the testing is required and beneficial for diagnosis and treatment.

    Routine flow cytometry-derived DNA Index, S-phase fraction, or percentage S-phase testing used for prognostic or therapeutic purposes in routine clinical cancer management does not meet coverage criteria.

    Codes 88187, 88188, and 88189 must not be used together for a single specimen in any combination. Each code is reimbursed at one unit per specimen, for up to two specimens per date of service.

    Codes 88187–88189 must not be billed in conjunction with cell-enumeration codes 86355, 86356, 86357, 86359, 86360, 86361, or 86367.

    The Bethesda recommendations state that flow cytometry is not indicated for mature neutrophilia, polyclonal hypergammaglobulinemia, polycythemia, thrombocytosis, or basophilia, because these findings generally are not associated with a flow-detectable hematolymphoid malignancy.

    Available evidence does not support routine flow-cytometric DNA ploidy, DNA Index, or S-phase/proliferation analysis as a prognostic or management tool. Guidance specifically does not recommend these tests for early-stage colorectal cancer, reports insufficient evidence for routine use in breast cancer, and identifies insufficient definitive evidence for routine ploidy analysis in endometrial cancer.

    Molar pregnancy screening is excluded as a flow cytometry indication because screening for molar pregnancy is no longer performed by flow cytometry.

    Routine measurement of flow cytometry-derived DNA content or cell proliferative activity for cancer prognosis or therapy is not medically necessary. The policy cites insufficient published scientific literature confirming that this testing is required and beneficial for diagnosis and treatment.

    Flow-cytometrically derived DNA ploidy or DNA flow-cytometric proliferation analysis should not be used to determine prognosis in early-stage colorectal cancer; the cited guidance considers such use, at best, experimental.

    Routine use of DNA ploidy by flow cytometry in breast cancer is not supported by sufficient evidence for routine clinical practice.

    Flow cytometry-derived DNA content, DNA Index, S-phase fraction, or percentage S-phase used for prognostic or therapeutic purposes in routine cancer management does not meet coverage criteria because sufficient published evidence of clinical benefit is lacking.

    Coding and Reimbursement

    Flow cytometric immunophenotyping for potential hematolymphoid neoplasiaCPTCovered
    88184Flow cytometric immunophenotyping for assessment of potential hematolymphoid neoplasia; first marker per specimen
    88185Flow cytometric immunophenotyping for assessment of potential hematolymphoid neoplasia; each additional marker
    88186Flow cytometric immunophenotyping for assessment of potential hematolymphoid neoplasia
    88187Flow cytometry interpretation code for assessment of potential hematolymphoid neoplasia
    88188Flow cytometry interpretation code for assessment of potential hematolymphoid neoplasia
    88189Flow cytometry interpretation code for assessment of potential hematolymphoid neoplasia
    Cell enumerationCPTCovered
    86355Cell enumeration
    86356Cell enumeration
    86357Cell enumeration
    86359Cell enumeration
    86360Cell enumeration
    86361Cell enumeration
    86367Cell enumeration
    Applicable CPT/HCPCS Procedure CodesCPT
    86355B cells, total count
    86356Mononuclear cell antigen, quantitative (eg, flow cytometry), not otherwise specified, each antigen
    86357Natural killer (NK) cells, total count
    86359T cells; total count
    86360T cells; absolute CD4 and CD8 count, including ratio
    86361T cells; absolute CD4 count
    86367Stem cells (ie, CD34), total count
    88182Flow cytometry, cell cycle or DNA analysis
    88184Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker
    88185Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)
    1–10 of 13
    1/2
    Flow cytometry reimbursement limitationsCPT
    88187Flow cytometry reimbursement-limited code; one unit per specimen, up to two specimens per date of service, and not used together with 88188 or 88189 for a single specimen.
    88188Flow cytometry reimbursement-limited code; one unit per specimen, up to two specimens per date of service, and not used together with 88187 or 88189 for a single specimen.
    88189Flow cytometry reimbursement-limited code; one unit per specimen, up to two specimens per date of service, and not used together with 88187 or 88188 for a single specimen.
    Removed CPT codeCPTNot Covered
    88199Removed from the policy.
    CPT 88184
    Code88184
    UseFirst marker per specimen
    Maximum reimbursementUp to 2 units per date of service
    CPT 88185
    Code88185
    UseEach additional marker
    Maximum reimbursement

    Provider and Billing Actions

    Documentation Required

    Match Reagent Panels to Clinical and Specimen Information

    Select flow cytometry reagent panels according to the specimen type, relevant clinical information, and cell morphology studies. Initial panels may range from 4 to 12 reagents, while secondary panels for inconclusive or noninformative evaluations may range from 5 to 23 reagents and should be indication-specific.

    • Consider whether the specimen is peripheral blood, bone marrow, tissue, or another body fluid.
    • Use diagnostically relevant initial and secondary reagent panels based on the clinical indication and morphology.
    Documentation Required

    Provide Complete Referral Records

    When referring a patient to another institution for treatment, provide the receiving treatment center with the complete clinical and laboratory record needed for continued care. Forward pending test results when they become available.

    • All laboratory results
    • Pathology slides
    • Flow cytometry data

    Background

    Flow cytometry analyzes the optical and fluorescence characteristics of individual cells or particles. It can assess features such as cell number, size, shape, viability, granularity, and biomarker expression, with immunophenotyping being a principal clinical application.

    Definitions and Abbreviations

    AIDS
    AbbreviationAIDS
    DefinitionAcquired immune deficiency syndrome
    Policy useT-cell monitoring for HIV infection and AIDS meets coverage criteria
    FCI
    AbbreviationFCI
    DefinitionFlow cytometric immunophenotyping
    Clinical useUsed to characterize cellular antigen expression and distinguish acute leukemia lineages

    Covered Clinical Indications

    Flow cytometry immunophenotyping of cell surface markers

    Coverage is available for flow cytometry immunophenotyping of cell surface markers when a covered hematologic, immunologic, platelet, or red-cell or white-cell indication applies.

    Covered disease or monitoring indication

    • The individual has cytopenias, lymphoma, leukemia, a myeloproliferative or lymphoproliferative disorder, or myelodysplastic syndrome.
    • B-cell monitoring is required for an immunosuppressive disorder.
    • T-cell monitoring is required for HIV infection or AIDS.
    • The individual has a mast cell neoplasm, paroxysmal nocturnal hemoglobinuria, or a plasma cell disorder.

    Frequency and Unit Limits

    Frequency limit: CPT 88184
    CodeCPT 88184
    Marker designationFirst marker per specimen
    Frequency limitMaximum of 2 units per date of service
    Frequency limit: CPT 88185
    CodeCPT 88185
    Marker designationEach additional marker
    Frequency limitMaximum of 35 units per date of service

    Ordering Requirements

    Documentation Required

    Obtain adequate specimens and order the appropriate workup

    For the acute leukemia workup, obtain sufficient specimens and perform or order flow cytometric immunophenotyping with morphologic assessment, conventional cytogenetic analysis, and appropriate molecular genetic and/or FISH testing. Ensure the flow cytometry analysis or molecular characterization is comprehensive enough to allow subsequent minimal residual disease detection.

    • The panel should distinguish acute myeloid leukemia, T-cell acute lymphoblastic leukemia, B-cell precursor acute lymphoblastic leukemia, and acute leukemia of ambiguous lineage.
    • If sufficient bone marrow aspirate or peripheral blood is unavailable, limited immunophenotyping by immunohistochemistry may be used as an alternative.

    Noncovered Services and Uses

    Flow cytometry-derived DNA content, DNA Index, S-phase fraction, or percentage S-phase testing is not covered when used for routine cancer prognosis or therapeutic decision-making.

    Flow cytometry is not covered or indicated for mature neutrophilia, polyclonal hypergammaglobulinemia, polycythemia, thrombocytosis, or basophilia.

    Unsupported or non-indicated uses include routine flow-cytometric DNA ploidy or proliferation analysis for cancer prognosis or management, including early-stage colorectal cancer, breast cancer, and other cancers for which cited guidance does not support routine use.

    Flow cytometry-derived DNA content, DNA Index, S-phase fraction, or percentage S-phase is not covered when used for routine cancer prognosis or therapy.

    Molar pregnancy screening by flow cytometry is not covered because this screening is no longer performed using flow cytometry.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyFlow Cytometry
    Policy CodePolicy N/A
    Change TypeRevision
    Effective DateFeb 1, 2026
    Last ReviewOct 31, 2025
    Next Review DateN/A
    Key ActionSelect the initial flow cytometry reagent panel based on specimen type, clinical information, and cell morphology studies.
    SourceLink
    On This Page
    Coverage CriteriaCoding and ReimbursementProvider and Billing ActionsBackgroundDefinitions and AbbreviationsCovered Clinical IndicationsFrequency and Unit LimitsOrdering RequirementsNoncovered Services and Uses
    A covered patient monitoring indication applies.
    Assessment of increased platelet activation in prothrombotic syndromes.
  1. Monitoring, when applicable, of the pharmacodynamic effect of P2Y12 antagonists using an appropriately designed test such as VASP P2Y12.
  2. Determination of the immature platelet fraction.
  3. Up to 35 units per date of service
    CPT 88187–88189
    Codes88187, 88188, and 88189
    ReimbursementOne unit per specimen
    Specimen limitUp to 2 specimens per date of service
    Cell-enumeration codes
    Codes86355, 86357, 86359, 86360, 86361, or 86367
    ServiceCell enumeration
    Unit limitationReimbursable as single units only
    Flow cytometry specimen reimbursement
    Codes88187, 88188, and 88189
    Reimbursement1 unit per specimen
    Daily specimen limitUp to 2 specimens per date of service
  4. Cytogenetic information
  5. Relevant clinical information and a list of pending tests
  6. Billing Rule

    Follow Coding and Unit Limits

    Apply the flow cytometry coding and unit limits carefully to avoid denials or payment reductions. Use codes according to marker, specimen, and service requirements, and limit testing to diagnostically relevant markers when the neoplasm has an established immunophenotype.

    • Use 88184 for the first marker per specimen, up to 2 units per date of service.
    • Use 88185 for each additional marker, up to 35 units per date of service.
    • Use 86355, 86357, 86359, 86360, 86361, or 86367 for cell enumeration; these codes are reimbursable as single units only.
    • Do not use codes 88187-88189 with 86355, 86356, 86357, 86359, 86360, 86361, or 86367.
    Denial Risk

    Routine DNA or S-Phase Cancer Testing Is Not Covered

    Routine testing of cancer DNA content or cell-cycle activity is not covered when performed for prognostic or therapeutic purposes. Claims for flow cytometry-derived DNA index, S-phase fraction, or percentage S-phase used in routine cancer management may be denied.

    • DNA index or DNA ploidy testing
    • S-phase fraction or percentage S-phase analysis
    • Routine prognostic, treatment-selection, or therapeutic cancer management use
    Denial Risk

    Avoid Unsupported or Non-Indicated Uses

    Do not order flow cytometry for conditions for which it is generally not indicated or for unsupported uses lacking evidence of diagnostic or treatment benefit. The Bethesda recommendations identify several findings that are usually not associated with a detectable hematolymphoid malignancy by flow cytometry.

    • Mature neutrophilia
    • Polyclonal hypergammaglobulinemia
    • Polycythemia
    • Thrombocytosis
    • Basophilia
    • Other uses not supported by the clinical indication, specimen findings, or available evidence
    Denial Risk

    Cancer DNA Content or Proliferation Analysis Is Not Covered

    Measurement of flow cytometry-derived DNA content or cell proliferative activity does not meet coverage criteria when used routinely for cancer prognosis or therapeutic management. Published evidence is insufficient to confirm that these tests are required and beneficial for diagnosis and treatment; flow cytometric DNA ploidy or proliferation testing should, at best, be considered experimental for routine clinical use.

    • DNA index or DNA ploidy analysis is not covered for routine prognostic or therapeutic cancer use.
    • S-phase fraction or percentage S-phase analysis is not covered for routine prognostic or therapeutic cancer use.

    Unsupported block type: documentation

    Billing Rule

    Observe Specimen and Unit Reimbursement Limits

    Codes 88187, 88188, and 88189 are mutually exclusive for a single specimen and are subject to specimen-based reimbursement limits. Do not report them together for one specimen, and do not exceed the allowance for two specimens on the same date of service.

    • Codes 88187, 88188, and 88189 cannot be combined for one specimen in any combination.
    • Each of codes 88187, 88188, and 88189 is reimbursed at 1 unit per specimen.
    • Limit reimbursement to a maximum of 2 specimens per date of service.
    FCM
    AbbreviationFCM
    Full termFlow cytometric immunophenotyping
    Related termFlow cytometry
    MRD
    AbbreviationMRD
    DefinitionMinimal residual disease
    Related policyFlow cytometry for MRD is covered in accordance with Avalon Policy AHS M2175-Minimal Residual Disease (MRD)
    SPF
    AbbreviationSPF
    DefinitionS-phase fraction
    Coverage contextRoutine S-phase fraction measurement for prognostic or therapeutic purposes in cancer management does not meet coverage criteria
    PIDs
    AbbreviationPIDs
    DefinitionPrimary immunodeficiencies
    Policy useFlow cytometry immunophenotyping for individuals with primary immunodeficiencies meets coverage criteria
    Laboratory-developed test (LDT)
    TermLaboratory-developed test (LDT)
    DefinitionA test developed and validated by an individual laboratory
    Regulatory contextRegulated by CMS as a high-complexity test under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88); not approved or cleared by the FDA
    Flow cytometric immunophenotyping (FCI)
    TermFlow cytometric immunophenotyping (FCI)
    DefinitionUse of flow cytometry to characterize cellular antigen expression
    Clinical useDistinguishes acute myeloid leukemia, T-cell acute lymphoblastic leukemia, B-cell precursor acute lymphoblastic leukemia, and acute leukemia of ambiguous lineage
    The individual has a primary immunodeficiency, non-neoplastic primary platelet disorder, or non-neoplastic red-cell or white-cell disorder.
  7. Preoperative or postoperative monitoring is required for an individual who will undergo or has undergone organ transplantation.
  8. Evaluation of cytopenias, elevated leukocyte count, atypical cells or blasts, body fluids, plasmacytosis or monoclonal gammopathy, organomegaly, tissue masses, and selected monitoring indications

    Flow cytometry may be used when clinically indicated for the following evaluations.

    Evaluation or monitoring indication

    • Evaluation of cytopenias.
    • Evaluation of an elevated leukocyte count.
    • Evaluation of atypical cells or blasts.
    • Evaluation of body fluids.
    • Evaluation of plasmacytosis or monoclonal gammopathy.
    • Evaluation of organomegaly or tissue masses.
    • A covered patient monitoring indication applies.

    Initial diagnostic workup of suspected or confirmed acute leukemia

    Flow cytometric immunophenotyping is covered as part of the initial diagnostic workup of suspected or confirmed acute leukemia.

    Acute leukemia lineage assessment: Perform flow cytometric immunophenotyping with morphologic assessment, conventional cytogenetic analysis, and appropriate molecular genetic and/or FISH testing. The panel must distinguish acute myeloid leukemia, T-cell acute lymphoblastic leukemia, B-cell precursor acute lymphoblastic leukemia, and acute leukemia of ambiguous lineage.

    If sufficient bone marrow aspirate or peripheral blood is unavailable, limited immunophenotyping by immunohistochemistry may be used.

    Evaluation of cerebrospinal fluid in patients with suspected or confirmed acute leukemia

    Flow cytometry may be used for cerebrospinal fluid evaluation in patients with suspected or confirmed acute leukemia.

    Acute leukemia CSF evaluation: The patient has suspected or confirmed acute leukemia and cerebrospinal fluid evaluation is clinically indicated.

    Inherited and acquired platelet disorders, platelet activation, P2Y12 antagonist monitoring, and immature platelet fraction determination

    Flow cytometric analysis may be used for selected inherited and acquired platelet disorders and related monitoring.

    Platelet testing indication

    • The test evaluates platelet surface glycoprotein deficiencies, alpha-granule secretion defects, platelet activation or signaling pathway defects, GFI1B macrothrombocytopenia, or platelet procoagulant activity disorders.
    • The test assesses increased platelet activation in a prothrombotic syndrome.
    • The test monitors the pharmacodynamic effect of a P2Y12 antagonist using an appropriately designed test such as VASP P2Y12.
    • The test determines the immature platelet fraction.

    Cytopenias, lymphomas, leukemia, myeloproliferative and lymphoproliferative disorders, or myelodysplastic syndrome

    Flow cytometry immunophenotyping is covered when clinically indicated for these hematologic disorders.

    Hematologic disorder indication

    • The individual has cytopenias, lymphoma, leukemia, a myeloproliferative or lymphoproliferative disorder, or myelodysplastic syndrome.

    Preoperative or postoperative monitoring of individuals undergoing or having undergone organ transplantation

    Coverage includes monitoring associated with organ transplantation.

    Transplantation monitoring

    • The individual will undergo organ transplantation and requires preoperative monitoring.
    • The individual has undergone organ transplantation and requires postoperative monitoring.

    Primary immunodeficiencies

    Coverage includes evaluation of individuals with primary immunodeficiencies.

    Primary immunodeficiency: The individual has a primary immunodeficiency.

    Minimal residual disease

    Minimal residual disease testing is covered subject to the separate Avalon policy.

    Minimal residual disease: Flow cytometry is used for minimal residual disease evaluation.

    Coverage must be determined in accordance with Avalon Policy AHS M2175-Minimal Residual Disease (MRD).

    Frequency limit: CPT 88187–88189
    CodesCPT 88187, 88188, or 88189
    Unit limitOne unit per specimen
    Specimen limitUp to two specimens per date of service
    Frequency limit: cell enumeration
    CodesCPT 86355, 86357, 86359, 86360, 86361, or 86367
    ServiceCell enumeration
    Frequency limitSingle units only
    Specimen reimbursement limit
    Codes88187, 88188, and 88189
    Reimbursed unitsOne unit per specimen
    Date-of-service limitUp to two specimens per date of service